Check out our latest case study by Gabriel Investment Syndicate.
“As work continues at home with the expansion of their Carcino3D™ technology into three new cancers (Ovarian, Colorectal and Lung) doubling their previous offering, they are now looking to focus on commercialisation. Ishani is heading to the US in November to generate leads and business within this very profitable market. They also continue to invest in efforts to develop further cancer models with several exciting projects currently in the pipeline.”
Read the full article here